Giants of Cancer Care® Program Inductees
Pediatric Oncology
Ching-Hon Pui, MD
Member, St. Jude Faculty
Co-leader, Hematological Malignancies Program
Director, China Region, St. Jude Global
Fahad Nassar Al-Rashid Endowed Chair of Leukemia Research
St. Jude Children’s Research Hospital
- Pui is a recipient of the 2022 ASPHO Distinguished Career Award.
- He was president of the Society of Hematologic Oncology in 2019.
- Research that Pui has conducted in the United States and in China has shown that economic intervention improves outcomes for pediatric patients with acute lymphoblastic leukemia (ALL) who have economic difficulties and/or reside in low-income regions.
- Pui led research showing that with the use of risk-adjusted chemotherapy, prophylactic cranial irradiation, a historic standard of care, is safe to be omitted from pediatric patients with ALL.
- He led the first randomized, phase 3 trial comparing the efficacy of dasatinib vs imatinib in pediatric Philadelphia chromosome–positive ALL, which was conducted across 20 hospitals in China. This trial demonstrated respective 4-year event-free survival and overall survival rates of 71.0% and 88.4% with dasatinib vs 48.9% and 69.2% with imatinib and revealed that dasatinib controlled central nervous system leukemia without prophylactic cranial irradiation.
- Pui also conducted research demonstrating that sequential minimal residual disease measurement can guide ALL treatments and help avoid overtreatment or undertreatment in patients with ALL.
Home
SUPPORTED BY
